Neuromyelitis optica spectrum disorder
Not yet recruitingRavulizumab versus plasma exchange for acute neuromyelitis optica attacks: a randomized trial in patients with first or relapsed episodes
Ravulizumab versus plasma exchange for acute neuromyelitis optica attacks: a randomized trial in patients with first or relapsed episodes
- Disease:Neuromyelitis optica spectrum disorder
- Substances:Ravulizumab
France- Participants:18–64 years · 65+ years
- Substances:Ravulizumab
- Sponsor:Les Hopitaux Universitaires De Strasbourg









